Table 1.
Studies’ characteristics.
| Single Arm Studies | ||||||
|---|---|---|---|---|---|---|
| Name | Country | Study Design | Study Year | Population | N of Participant, Total (MIS/OSS) ^ | Mean FUP Months |
| Colomer 2008 [8] | Spain | Prospective Monocentric study | 2003–2007 | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 19 | 24.7 |
| Facer 2019 [21] | USA | Retrospective Cohort Multicentric Study | 2010–2014 | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 1901 | 37.6 |
| Gallotta 2021 [22] | Italy | Retrospective Observational Multicentric Study | 2008–2016 | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 254 | 61 |
| Ghezzi 2011 [23] | Italy | Retrospective Observational Multicentric study | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 82 | 28.5 | |
| Lee 2017 [24] | Taiwan | Retrospective Observational Monocentric study | 2002–2014 | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 24 | 31.5 |
| Muzii 2008 [25] | Italy | Prospective Observational Monocentric study | 2003–2013 | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 27 | 20 |
| Nezhat 2008 [10] | USA | Retrospective Observational Monocentric study | 1995–2007 | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 36 | 55.9 |
| Tozzi 2003 [26] | Germany | Prospective Observational Monocentric study | 1996–2003 | Apparent early-stage epithelial ovarian cancer undergoing MIS staging | 24 | 46.4 |
| Comparative Studies | ||||||
| Chi 2005 [27] | USA | Retrospective Case-Control Monocentric Study | 2000–2003 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 50 (20/30) |
46 |
| Ditto 2016 [28] | Italy | Retrospective Case-Control Multicentric study | 2005–2015 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 100 (50/50) |
51.1 |
| Gallotta 2016 [29] | Italy | Retrospective Case-Control Multicentric study | 2000–2013 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 180 (60/120) |
38 |
| Koo 2014 [30] | Korea | Retrospective Case-Control Monocentric study | 2006–2012 | Apparent early stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 77 (24/53) | 31 |
| Liu 2013 [31] | China | Retrospective Case-Control Monocentric study | 2002–2010 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 75 (35/40) | 84 |
| Lu 2016 [32] | China | Retrospective Case-Control Monocentric study | 2002–2014 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 92 (42/50) | 82 |
| Melamed 2016 [33] | USA | Retrospective Observational Multicentric study | 2010–2012 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 4798 (1112/3686) | 29.9 |
| Merlier 2020 [34] | France | Retrospective Case-Control Multicentric study | 2000–2018 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 144 (37/107) | 36 |
| Minig 2016 [35] | Spain | retrospective comparative observational study | 2006–2014 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 108 (50/58) | 30.4 |
| Park 2008 [11] | USA | Retrospective Case-Control Monocentric study | 2004–2007 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 52 (19/33) | 17 |
| Wu 2009 [36] | Taiwan | Retrospective Case-Control Monocentric study | 1984–2006 | Apparent early-stage epithelial ovarian cancer undergoing MIS vs. OSS staging | 208 (34/174) | 65 |
MIS: Minimally Invasive Surgery; OSS: Open Surgical Staging; FUP: Follow-Up. ^ Sub-analysis of the entire cohort.